KNSA: Kiniksa Pharmaceuticals, Ltd. Company Value to Net Income

Kiniksa Corp - graphic logo of issuer KNSA

Kiniksa Pharmaceuticals dominates the orphan disease niche thanks to the monopoly status of ARCALYST. The company's price-to-earnings ratio clearly confirms the market valuation of this advantage, where 42.00 expresses the metric's value today. Business resilience is based on scientific data, ignoring economic cycles. The risks of a narrow portfolio are mitigated by expanding the list of approved indications for the primary drug.

Kiniksa (KNSA) Price to Earnings Ratio: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Kiniksa Corp (KNSA)

Comprehensive company analysis:Kiniksa KNSA
Signature product of Kiniksa Pharmaceuticals Ltd

The P/E ratio measures the market value of a single unit of profit, reflecting investor expectations regarding the capitalization rates of an asset's future earnings. By analyzing the base P/E of Kiniksa Pharmaceuticals (KNSA) on the GURU.Markets platform, one can assess the fairness of the valuation for Kiniksa Pharmaceuticals, whose value relies on the commercial success of drugs for treating rare autoimmune pathologies within the specialized immunology segment.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Grifols SA (GRFS) - Price to Earnings Ratio|Adaptive Biotechnologies Inc. (ADPT) - Price to Earnings Ratio|Price to Earnings Ratio Celldex Therapeutics|Price to Earnings Ratio AUPH|P/E Multiple biocryst.com|Price to Earnings Ratio Vera Pharma (VERA)|Dianthus Therapeutics, Inc. - Price to Earnings Multiple|P/E Multiple PHVS (pharvaris.com)|AbCellera Bio (ABCL) - Market Cap to Earnings|TRML: Price to Earnings Ratio|Market Cap to Net Income PGEN|PHAR: P/E Multiple|Market Cap to Earnings Nektar Therapeutics Inc (NKTR)|Price to Earnings Ratio UPB|Price to Earnings Multiple ZBIO (Zenas Biopharma, Inc.)|Price to Earnings Ratio IMNM (Immunome Bio)|Business Payback Period Gossamer Bio, Inc.|P/E Multiple KALV (KalVista Pharma)|Septerna, Inc. (SEPN) - Market Cap to Earnings|PVLA - Price to Earnings Ratio|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|ANAB - Business Payback Period|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|Price to Earnings Ratio RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Company Value to Net Income|P/E Multiple ACRS (Aclaris Therapeutics)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX (Theratechnologies, Inc) - Price to Earnings Ratio|AVTX (Avalo Therapeutics, Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals|Price to Earnings Ratio Agenus Inc. (AGEN)|Price to Earnings Ratio Climb Bio Inc. CLYM|P/E Multiple ZURA (Zura Bio Ltd)|ATYR - Price to Earnings Ratio|ADAG - Price to Earnings Ratio|IMA - P/E Multiple|STTK: P/E Multiple|Equillium Bio (EQ) - P/E Multiple|CNTB (connectbiopharm.com) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Market Cap to Net Income|P/E Multiple adicetbio.com ACET|Celularity - P/E Multiple|Company Value to Net Income INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Price to Earnings Ratio|Market Cap to Net Income KZR (Kezar Life Sciences)|Price to Earnings Ratio SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Market Cap to Net Income|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple